Table 1.
VH Gene Analysis in Normal and Malignant Human B Cells
| Cell type | Immunophenotype | Mutation frequency (%) | Microheterogeneity (ongoing mutations) | Reference No. |
|---|---|---|---|---|
| Normal B cell | ||||
| Naive | slgM+/slgD+, CD5+ | 0–0.3 | no | 5, 28 |
| Naive | slgM+/slgD+, CD5− | 0–1.5 | no | 5, 12 |
| GC | slgM+/slgD−, CD38+ | 0.3–4.3 | yes | 32, 35 |
| Memory | slgM+/slgD−, CD38− | 3.9 | no | 28, 29 |
| Plasma cell | slg−, CD38+ | 8 | no | 11 |
| B cell lymphoma | ||||
| B-CLL | slgM+/−slgD+/−, CD5+ | 0 | no | 39 |
| MCL | slgM+/slgD+, CD5+ | 0–2.2 | yes/no | 10, 23, 30 |
| Burkitt’s (endemic) | slgM+/slgD− | 5–15 | yes | 27, 55 |
| Burkitt’s (sporadic) | slgM+/slgD− | 0.3–5.6 | yes | 27, 55 |
| FL | slgM+/slgD− | 10.5 | yes | 58 |
| Nodal DLBL | slgM+/slgD− | 9.9 | yes | 31 |
| Extranodal DLBL | slgM+/slgD− | 11.5 | yes | 16 |
| MZBC of MALT-type | slgM+/slgD−, CD38− | 4–4.5 | yes | 46, 47 |
| Splenic lymphoma | slgM+/slgD−, CD38− | 4.2 | no | 59 |
| PEL | slg−, CD38+ | 7.7 | yes/no | 40 |
| Multiple myeloma | slg−, CD38+ | 8.9 | no | 56 |
slg: surface immunoglobulin; MCL: mantle cell lymphoma; FL: follicular lymphoma; DLL: diffuse large cell lymphoma; MALT: mucosa-associated lymphoid tissue; DLBL: diffuse large cell B cell lymphoma; MZBC: marginal zone B cell; PEL: primary effusion lymphoma.